Какова цена за NGM Biopharmaceuticals, Inc. (NGM)

Цена за NGM Biopharmaceuticals, Inc. (NGM) Это $1.54

Какова рыночная капитализация для NGM Biopharmaceuticals, Inc. (NGM)

Рыночная капитализация для NGM Biopharmaceuticals, Inc. (NGM) Это $119.21M

NGM Biopharmaceuticals, Inc. (NGM) Дивиденды

NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.

Год	Дивиденды (с учетом дробления акций)	Изменить
Недостаточно данных для указанных дат.

Год

Дивиденды (с учетом дробления акций)

Изменить

Недостаточно данных для указанных дат.

Год	Дивиденд	Изменить
Недостаточно данных для указанных дат.

Год

Дивиденд

Изменить

Недостаточно данных для указанных дат.

Компания	Количество дивидендных выплат	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Moderna, Inc. MRNA.US	0.00%	US
CSL Limited CSL.AX	64.00%	AU
Lonza Group AG LONN.SW	0.00%	CH

Компания

Количество дивидендных выплат

Страна